hcd19.il15.car-inkt
Cell therapyexperimental
Clinical trial activity
1 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 19, 2021 (NCT04814004)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04814004 | Phase 1 | Mar 19, 2021 | Huai'an First People's Hospital, Jiangsu University, Nanjing Medical University, Nantong University, The First People's Hospital of Changzhou, Xuzhou Medical University, Zhejiang University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huai'an First People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Jiangsu University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Nantong University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| The First People's Hospital of Changzhou | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Xuzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2021 |
7 organizations
Page 1 / 1